Amylyx 製藥公司

SecurityAMLX / Amylyx Pharmaceuticals, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership106,536 shares
Latest Disclosed Value $ 682,895
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series ownership in AMLX / Amylyx Pharmaceuticals, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 106,536 shares of Amylyx Pharmaceuticals, Inc. (US:AMLX) valued at $682,896 USD as of June 30, 2025. The entity filed a previous NPORT-P on November 26, 2024 disclosing 0 shares of Amylyx Pharmaceuticals, Inc.. The current value of the position is $1,524,530 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Amylyx Pharmaceuticals EC US03237H1014 106,536 106,536 683 0.0153
2024-11-26 2024-09-30 NP Amylyx Pharmaceuticals EC US03237H1014 0 -89,639 -100.00 0 -100.00
2024-08-26 2024-06-30 NP Amylyx Pharmaceuticals EC US03237H1014 89,639 0 0.00 170 -33.07 0.0035
2024-05-28 2024-03-31 NP Amylyx Pharmaceuticals EC US03237H1014 89,639 -2,804 -3.03 255 -81.32 0.0053
2024-02-26 2023-12-31 NP Amylyx Pharmaceuticals EC US03237H1014 92,443 5,837 6.74 1,361 -14.20 0.0290
2023-11-28 2023-09-30 NP Amylyx Pharmaceuticals EC US03237H1014 86,606 -1,163 -1.33 1,586 -16.27 0.0414
2023-08-25 2023-06-30 NP Amylyx Pharmaceuticals EC US03237H1014 87,769 7,771 9.71 1,893 -19.34 0.0449
2023-05-26 2023-03-31 NP Amylyx Pharmaceuticals EC US03237H1014 79,998 1,091 1.38 2,347 -19.49 0.0625
2023-02-24 2022-12-31 NP Amylyx Pharmaceuticals EC US03237H1014 78,907 23,601 42.67 2,916 87.34 0.0802
2022-11-25 2022-09-30 NP Amylyx Pharmaceuticals EC US03237H1014 55,306 37,518 210.92 1,557 354.97 0.0446
2022-08-25 2022-06-30 NP Amylyx Pharmaceuticals EC US03237H1014 17,788 4,070 29.67 343 94.32 0.0095
2022-05-26 2022-03-31 NP Amylyx Pharmaceuticals EC US03237H1014 13,718 13,718 176 0.0041
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.